Met receptor signaling: A key effector in esophageal adenocarcinoma

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 5936-5943

  Anderson, Mark R ^a,c,f   Harrison, Rebecca ^b   Atherfold, Paul A ^a   Campbell, Moray J ^c   Darnton, S Jane ^d   Obszynska, Jolanta ^c   Jankowski, Janusz A Z ^a,b,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CADHERIN; CATENIN; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ARTICLE; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; BASE SEQUENCE; CADHERINS; CELL LINE, TUMOR; DNA PRIMERS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INCIDENCE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33750719996     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1208     Document Type: Article

References (50)

1. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-9.
2. Reynolds JC, Waronker M, Pacquing MS, Yassin RR. Barrett's esophagus: reducing the risk of progression to adenocarcinoma. Gastroenterol Clin North Am 1999;28:917-45.
3. Morales TG, Sampliner RE. Barrett's esophagus, update on screening, surveillance and treatment. Arch Intern Med 1999;159:1411-6.
4. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
5. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
6. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
7. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary culture. Proc Natl Acad Sci U S A 1986;83:6489-93.
8. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985;77:209-23.
9. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59.
10. Kermorgant S, Walker F, Hormi K, Dessirier V, Lewin MJ, Lehy T. Developmental expression and functionality of hepatocyte growth factor and c-met in human fetal digestive tissues. Gastroenterology 1997;112:1635-47.
11. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-met oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 1991;49:323-8.
12. Jeffers M, Fiscella M, Webb CP. The mutationally activated met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998;95:14417-22.
13. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
14. Sanders DS, Bruton R, Darnton SJ, et al. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int J Cancer 1998;79:573-9.
15. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 2001;153:1049-60.
16. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity. J Cell Biol 2001;154:1185-96.
17. Stewart DB, Nelson WJ. Identification of four distinct pools of catenins in mammalian cells and transformation-dependent changes in catenin distributions among these pools. J Biol Chem 1997;272:29652-62.
18. Barker N, Morin P, Clevers H. The yin-yang of TCF/β-catenin signaling. Adv Cancer Res 2000;77:1-24.
19. Bailey T, Biddleston L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin/catenin complexes in the dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-44.
20. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-80.
21. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
22. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
23. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met with the cell-surface adhesion molecule, E-Cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-11.
24. Davies G, Jiang WG, Mason MD. Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion. Anticancer Res 1999;19:547-52.
25. Monga SPS, Mars WM, Padiaditakis P, et al. Hepatocyte growth factor induces wnt-independent nuclear translocation of β-catenin after met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71.
26. Herrera LJ, El-Hefanwy T, Querioz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005;7:75-84.
27. Saeki H, Oda S, Kawaguchi H, et al. Concurrent overexpression of ets-1 and c-met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 2002;98:8-13.
28. Porte H, Triboulet JP, Kotelevets L, et al. Overexpression of stromelysin-3, BM-40/SPARC and Met genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998;4:1375-82.
29. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999;86:2259-65.
30. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513-20.
31. Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 1997;75:258-63.
32. Nishihara T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441-9.
33. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571-8.
34. Hardy RG, Tselepis C, Hoyland J, et al. Aberrant P-cadherin expression is an early event in hyperplasia and dysplastic transformation in the colon. Gut 2002;50:513-9.
35. Parr C, Jiang WG. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-met receptor in human cancer cells. Int J Oncol 2001;19:857-63.
36. Wetering M, Cavallo R, Dooijes D, et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997;88:789-99.
37. Eliopoulos AG, Stack M, Dawson CW, et al. Epstein-Barr virus encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor associated factors. Oncogene 1997;14:2899-916.
38. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis α in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-81.
39. Perry I, Hardy R, Jones T, Jankowski J. A colorectal cell line with alterations in E-cadherin and epithelial biology may be an in-vitro model of colitis. Mol Pathol 1999;52:231-42.
40. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes S. Neu differentiation factor activation of erbB-3 and erbB-4 is specific and displays a differential requirement for erbB-2. Mol Cell Biol 1995;15:6494-505.
41. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Muhldorfer S. Activation of NFκB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPAR-γ and growth factors. Dig Dis Sci 2004;49:1075-83.
42. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. J Biol Chem 2000;275:8806-11.
43. Oshima M, Fujikawa K, Akutagawa H, Kato T, Ito K, Otsuka K. Hepatocyte growth factor is saliva: a possible marker for periodontal disease. J Oral Sci 2002;44:35-9.
44. Niki M, Isozaki H, Toyoda M, et al. Serum hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Hepatogastroenterology 1999;46:568-73.
45. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
46. Comijn J, Berx G, Vermessen P, Verschueren K, Van Grunsven L, Van Roy F. The two handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78.
47. Yi S, Tsao MS. Activation of hepatocyte growth factor - met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000;2:226-34.
48. Zeng Q, Chen S, You Z, et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFκB. J Biol Chem 2002;277:25203-8.
49. Sattler M, Pride YB, Ma P, et al. A novel small molecule inhibitor induces apoptosis in cells transformed by the oncogenic tpr-met tyrosine kinase. Cancer Res 2003;63:5462-9.
50. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004;41:267-73.